FMA
ITCI

FNY Managed Accounts’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

FNY Managed Accounts’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		$10K Buy
+500
New +$9.74K 0.01% 146

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FNY Managed Accounts's ITCI Position: Q1 2018 in Review

FNY Managed Accounts opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q1 2018: 500 shares worth $10K. The stake represents 0.01% of the portfolio and ranks #146 among its holdings.

131 funds tracked by Wall St. Rank hold ITCI as of Q1 2018.

  • FNY Managed Accounts held 500 shares of Intra-Cellular Therapies Inc. worth $10K as of Q1 2018.
  • Intra-Cellular Therapies Inc. was a new FNY Managed Accounts position in Q1 2018.
  • Intra-Cellular Therapies Inc. made up 0.01% of FNY Managed Accounts's portfolio in Q1 2018, its #146 holding.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2018.

Based on FNY Managed Accounts's 13F filing for Q1 2018, filed 18 Apr 2018.